In a study on the lung adenocarcinoma HCC827 cell line, Ni et al. (2017) showed that efatutazone, which acted as an upregulator for PPAR and PTEN and inactivator for Akt pathway, improved the action of TKI and could have therapeutic effects in cancer [137]. Here, PTEN is linked to cancer.